Show simple item record

dc.contributor.authorBolocan, Andrei S.
dc.contributor.authorUpadrasta, Aditya
dc.contributor.authorde Almeida Bettio, Pedro H.
dc.contributor.authorClooney, Adam G.
dc.contributor.authorDraper, Lorraine A.
dc.contributor.authorRoss, R. Paul
dc.contributor.authorHill, Colin
dc.date.accessioned2021-02-16T16:55:27Z
dc.date.available2021-02-16T16:55:27Z
dc.date.issued2019-04-20
dc.identifier.citationBolocan, A.S.; Upadrasta, A.; de Almeida Bettio, P.H.; Clooney, A.G.; Draper, L.A.; Ross, R.P.; Hill, C. Evaluation of Phage Therapy in the Context of Enterococcus faecalis and Its Associated Diseases. Viruses 2019, 11, 366. https://doi.org/10.3390/v11040366en_US
dc.identifier.urihttp://hdl.handle.net/11019/2373
dc.descriptionpeer-revieweden_US
dc.description.abstractBacteriophages (phages) or bacterial viruses have been proposed as natural antimicrobial agents to fight against antibiotic-resistant bacteria associated with human infections. Enterococcus faecalis is a gut commensal, which is occasionally found in the mouth and vaginal tract, and does not usually cause clinical problems. However, it can spread to other areas of the body and cause life-threatening infections, such as septicemia, endocarditis, or meningitis, in immunocompromised hosts. Although E. faecalis phage cocktails are not commercially available within the EU or USA, there is an accumulated evidence from in vitro and in vivo studies that have shown phage efficacy, which supports the idea of applying phage therapy to overcome infections associated with E. faecalis. In this review, we discuss the potency of bacteriophages in controlling E. faecalis, in both in vitro and in vivo scenarios. E. faecalis associated bacteriophages were compared at the genome level and an attempt was made to categorize phages with respect to their suitability for therapeutic application, using orthocluster analysis. In addition, E. faecalis phages have been examined for the presence of antibiotic-resistant genes, to ensure their safe use in clinical conditions. Finally, the domain architecture of E. faecalis phage-encoded endolysins are discussed.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofseriesViruses;366
dc.rightsAttribution-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/*
dc.subjectphage therapyen_US
dc.subjectE. faecalisen_US
dc.subjectOrthoMCLen_US
dc.titleEvaluation of Phage Therapy in the Context of Enterococcus faecalis and Its Associated Diseasesen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/v11040366
dc.contributor.sponsorScience Foundation Irelanden_US
dc.contributor.sponsorEuropean Unionen_US
dc.contributor.sponsorJanssen Biotech, Inc.en_US
dc.contributor.sponsorGrantNumberSFI/12/RC/2273en_US
dc.contributor.sponsorGrantNumberSFI/14/SP APC/B3032en_US
refterms.dateFOA2021-02-16T16:55:27Z


Files in this item

Thumbnail
Name:
viruses-11-00366-v2.pdf
Size:
7.547Mb
Format:
PDF
Description:
main article

This item appears in the following Collection(s)

Show simple item record

Attribution-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-ShareAlike 4.0 International